Polymyositis and dermatomyositis epidemiology and demographics

Revision as of 15:13, 9 April 2018 by Ssharfaei (talk | contribs) (→‎Age)
Jump to navigation Jump to search

Polymyositis and dermatomyositis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyositis and dermatomyositis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyositis and dermatomyositis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyositis and dermatomyositis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyositis and dermatomyositis epidemiology and demographics

CDC on Polymyositis and dermatomyositis epidemiology and demographics

Polymyositis and dermatomyositis epidemiology and demographics in the news

Blogs on Polymyositis and dermatomyositis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Polymyositis and dermatomyositis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide.[1]
  • In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually.[2]

Prevalence

  • The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide.[1]
  • In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec.[3]
  • In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.[2]

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].
  •  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%.[2]
  • The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years.[2]

Age

  • Patients of all age groups may develop polymyositis and dermatomyositis.
  • Dermatomyositis commonly affects both children and adults.[4]
  • Polymyositis is rare among children.[4]
  • Polymyositis and dermatomyositis commonly affects patients in 40-50 years of age.

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • Females are more commonly affected by polymyositis and dermatomyositis than males. The female to male ratio is approximately 2 to 1.

Region

  • Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.[5]

Developed Countries

Developing Countries

References

  1. 1.0 1.1 Jacobson DL, Gange SJ, Rose NR, Graham NM (September 1997). "Epidemiology and estimated population burden of selected autoimmune diseases in the United States". Clin. Immunol. Immunopathol. 84 (3): 223–43. PMID 9281381.
  2. 2.0 2.1 2.2 2.3 Airio, A.; Kautiainen, H.; Hakala, M. (2006). "Prognosis and mortality of polymyositis and dermatomyositis patients". Clinical Rheumatology. 25 (2): 234–239. doi:10.1007/s10067-005-1164-z. ISSN 0770-3198.
  3. Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.
  4. 4.0 4.1 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  5. Bernatsky, S; Joseph, L; Pineau, C A; Belisle, P; Boivin, J F; Banerjee, D; Clarke, A E (2008). "Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences". Annals of the Rheumatic Diseases. 68 (7): 1192–1196. doi:10.1136/ard.2008.093161. ISSN 0003-4967.

Template:WH Template:WS